Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR

OBJECTIVE: Pasireotide is a second-generation somatostatin receptor ligand (SRL) used for treating acromegaly. Its clinical use is limited by adverse effects on glucose homeostasis. The aim of this study was to evaluate longitudinal changes in beta-cell function and insulin sensitivity associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Peter, Dormoy, Alexandre, Maione, Luigi, Salenave, Sylvie, Young, Jacques, Kamenický, Peter, Chanson, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716376/
https://www.ncbi.nlm.nih.gov/pubmed/36269605
http://dx.doi.org/10.1530/EC-22-0296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716376/
https://www.ncbi.nlm.nih.gov/pubmed/36269605
http://dx.doi.org/10.1530/EC-22-0296

Ejemplares similares